This investment will be to develop a new high-tech manufacturing facility at its biopharmaceutical campus in Kinsale, Co. Cork, using pioneering technology that has the potential to transform how medicines are made in the future. The new facility will help develop and commercialise of a number of Lilly’s small molecule pipeline products that are currently undergoing late-stage clinical trials.
Eli Lilly said it is hoping to have the new Kinsale facility fully operational by early next year. The development will see the Kinsale site becoming the centre of excellence for continuous manufacturing for active pharmaceutical ingredients for Lilly worldwide.
This investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Eli Lilly employs around 1,000 people in Ireland in three operations, based in Kinsale, Cork City and Dublin.
Source: IDA Ireland